Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome

Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced positive interim results from its ongoing POLARIS ...

Here comes Krampus: How the half-goat, half-demon became a cultural phenomenon

While Santa Claus’ dark counterpart was born centuries ago in Europe, Krampus’ recent explosion in the U.S. is all thanks to ...

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted ...